An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.

CONCLUSIONS: Olaparib reduced expression of cyclin D1, which positively correlated with PARP-1 levels. This effect was more evident in ARID1A-deficient tumors. Olaparib further induced inhibition of GLUT1 plasma activity. Our findings could have noteworthy implications in predicting which patients with EC would benefit from olaparib-based strategies.
PMID: 32988624 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - September 24, 2020 Category: Cancer & Oncology Authors: Romero I, Rubio MJ, Medina M, Matias-Guiu X, Santacana M, Schoenenberger JA, Guerra EM, Cortés A, Minig L, Coronado P, Cueva JF, Gómez L, Malfettone A, Sampayo M, Llombart-Cussac A, Poveda A Tags: Gynecol Oncol Source Type: research